γδ T cells in AML

  • Research type

    Research Study

  • Full title

    Assessing feasibility of expansion and characterization of γδ T cells from peripheral blood and bone marrow of patients with Acute Myeloid Leukaemia as starting product for generation of CD33-CD28 γδ T cells.

  • IRAS ID

    239062

  • Contact name

    Chloe McCormack

  • Contact email

    chloe.mccormack@rmh.nhs.uk

  • Sponsor organisation

    The Royal Marsden NHS Foundation Trust

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    The Royal Marsden NHS Foundation Trust is committed to improving patient experience; this research is being undertaken to try to develop a novel treatment for patients with Acute Myeloid Leukaemia (AML). We want to develop a new therapy which uses a patients own immune cells called T cells to treat AML. The starting point with this study is to demonstrate whether sufficient numbers of T cells can be collected from the blood of patients with AML at various points throughout their treatment. Blood samples will be collected at the same time as the patient’s bone marrow test. If patients need further bone marrow tests during their course of treatment to assess the status of disease, we would ask that additional samples are taken at the same time as the bone marrow and blood will be collected at the same time as the routine blood draw.
    Following collection of blood samples, the blood samples will be used to purify a population of blood cells called Gamma Delta T cells which have been shown to have a potential role in control of cancers. In addition we plan to determine whether we can put a novel receptor called a chimeric antigen receptor (CAR) to potentially directly target leukaemia cells. Currently this is only an exploratory study and none of the samples collected will be used for treatment but is only to assess whether or not this strategy is feasible. This may however lead on to studies in the future looking at the safety and effectiveness of this strategy. This hopefully will lead in the future to improvements in treatment and outcome for patients with AML.

  • REC name

    Wales REC 6

  • REC reference

    18/WA/0103

  • Date of REC Opinion

    5 Mar 2018

  • REC opinion

    Favourable Opinion